Who
Curran Simpson
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Regenxbio; Sr. VP, Operations, Human Genome Sciences.
In numbers
- Trades disclosed
- 268
- Buys
- 0
- Sells
- 34
- Bought
- $0
- Sold
- $25.8M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 14 Mar 2006
- Last trade
- 1 Jul 2026
- Last filed
- 6 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 6 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $89K6,818 at $13.09 | filing |
| 1 Jul 2026filed 6 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $89K6,818 at $13.09 | filing |
| 30 Jun 2026filed 6 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | $15K1,453 at $10.18 | filing |
| 30 Jun 2026filed 6 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | $15K1,453 at $10.18 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —144,864 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —233,651 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —233,651 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —144,864 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $267K18,559 at $14.40 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $267K18,559 at $14.40 | filing |
| 31 Dec 2025filed 6 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | $6,653951 at $7.00 | filing |
| 31 Dec 2025filed 6 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | $6,657951 at $7.00 | filing |
| 9 Oct 2025filed 10 Oct 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $263K20,811 at $12.62 | filing |
| 29 Sep 2025filed 1 Oct 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $76K7,624 at $10.03 | filing |
| 10 Sep 2025filed 12 Sep 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $77K7,734 at $10.02 | filing |
| 1 Jul 2025filed 3 Jul 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $39K4,701 at $8.23 | filing |
| 2 Jan 2025filed 14 Jan 2025 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —478,606 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —476,606 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $92K11,917 at $7.73 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —98,912 at $0.00 | filing |
News
Contrasting Cue Biopharma (NASDAQ:CUE) & REGENXBIO (NASDAQ:RGNX)RGNX · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Curran Simpson; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.